ATX 0.00% 15.5¢ amplia therapeutics limited

Ann: Update on ACCENT Trial in Pancreatic Cancer, page-12

  1. 507 Posts.
    lightbulb Created with Sketch. 236
    I take from this that what’s reported were the best responses at any time on trial, according to Recist criteria. Ultimately all patients progress, my hunch is that those that left the trial is because they progressed and maybe gone onto other chemo, or maybe another clinical trial. The 3 remaining haven’t progressed yet.
 
watchlist Created with Sketch. Add ATX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.